A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants (POSTERITY)

June 1, 2026 updated by: Hoffmann-La Roche

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescent Patients With Active Class III or IV Lupus Nephritis, Including an Evaluation of Open Label Safety and PK in a Cohort of Pediatric Patients (Aged 5 to < 12)

This phase II, randomized, double-blind, placebo-controlled study is designed to evaluate the safety, efficacy and pharmacokinetics (PK) of obinutuzumab in adolescent participants (AP) aged 12 to less than 18 with biopsy-confirmed proliferative lupus nephritis (LN). It will also evaluate open label safety and PK of obinutuzumab in pediatric participants (PP), aged 5 to <12 with LN.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
40

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Contact Backup

  • Name: Fastest response: use the inquiry form. No email attachments. https://www.gene.com/contact-us/submit-medical-inquiry

Study Locations

  • Brazil
      • São Paulo, Brazil, 04024-002
        • Active, not recruiting
        • Universidade Federal de Sao Paulo - UNIFES
    • Estado de Bahia
      • Salvador, Estado de Bahia, Brazil, 40150-150
        • Recruiting
        • Ser Servicos Especializados Em Reumatologia
    • São Paulo
      • Campinas, São Paulo, Brazil, 13060-904
        • Recruiting
        • Centro de Pesquisa Sao Lucas
      • São Paulo, São Paulo, Brazil, 05403-000
        • Recruiting
        • Hospital das Clinicas - FMUSP
  • Canada
    • Ontario
      • Toronto, Ontario, Canada, M5G 1X8
        • Recruiting
        • The Hospital for Sick Children
    • Quebec
      • Montreal, Quebec, Canada, H3T 1C5
        • Recruiting
        • Hospital Sainte-Justine
  • France
      • Le Kremlin-Bicêtre, France, 94275
        • Recruiting
        • CH de Bicêtre
      • Paris, France, 75019
        • Recruiting
        • Hôpital Robert Debré
      • Paris, France, 75743
        • Recruiting
        • Hop Necker Enfants Malades
      • Toulouse, France, 31000
        • Recruiting
        • CHU de Toulouse - Hôpital des Enfants
  • Italy
    • Lazio
      • Rome, Lazio, Italy, 00165
        • Recruiting
        • Ospedale Pediatrico Bambino Gesu
    • Liguria
      • Genoa, Liguria, Italy, 16148
        • Recruiting
        • IRCCS G. Gaslini
    • Lombardy
      • Milan, Lombardy, Italy, 20122
        • Recruiting
        • Clinica Pediatrica II De Marchi
  • Mexico
    • Jalisco
      • Guadalajara, Jalisco, Mexico, 44620
        • Recruiting
        • CREA Hospital Mexico Americano
    • Mexico CITY (federal District)
      • Mexico City, Mexico CITY (federal District), Mexico, 06700
        • Recruiting
        • Clinstile S.A de C.V.
    • Nuevo León
      • Monterrey, Nuevo León, Mexico, 64460
        • Recruiting
        • Hospital Universitario Dr. Jose Eleuterio González
  • Peru
      • Lima, Peru
        • Active, not recruiting
        • Instituto de Ginecología y Reproducción
      • San Isidro, Peru, L27 Lima
        • Active, not recruiting
        • Clinica El Golf
  • Poland
      • Gdansk, Poland, 80-294
        • Recruiting
        • Uniwersyteckie Centrum Kliniczne
      • Torun, Poland, 87-100
        • Withdrawn
        • Szpital Specjalistyczny dla Dzieci i Doroslych
  • Russia
    • Sankt-Peterburg
      • St-peterburg, Sankt-Peterburg, Russia, 194100
        • Withdrawn
        • Saint-Petersburg State
  • South Africa
      • Cape Town, South Africa, 7700
        • Withdrawn
        • Red Cross War Memorial Children?s Hospital
      • Cape Town, South Africa, 7925
        • Withdrawn
        • Groote Schuur Hospital
      • Panorama, South Africa, 7500
        • Recruiting
        • Panaroma Medical Center
  • Spain
      • Madrid, Spain, 28034
        • Recruiting
        • Hospital Ramon y Cajal
      • Madrid, Spain, 28046
        • Recruiting
        • Hospital de La Paz
      • Valencia, Spain, 46026
        • Recruiting
        • Hospital Universitario la Fe: Servicio de Reumatologia Pediatrica
    • Barcelona
      • Esplugas de Llobregat, Barcelona, Spain, 08950
        • Recruiting
        • Hospital Sant Joan de Déu
  • United Kingdom
      • Glasgow, United Kingdom, G51 4TF
        • Withdrawn
        • Royal Hospital For Children
      • Liverpool, United Kingdom, L12 2AP
        • Recruiting
        • Alder Hey Childrens Hospital
      • London, United Kingdom, WC1N 3JH
        • Recruiting
        • Great Ormond Street Hospital for Children
  • United States
    • California
      • Loma Linda, California, United States, 92354
        • Recruiting
        • Loma Linda University Health
      • San Francisco, California, United States, 94158
        • Recruiting
        • UCSF Benioff Childrens Hospital
    • Colorado
      • Aurora, Colorado, United States, 80045
        • Recruiting
        • Children's Hospital Colorado, Anchutz Medical Campus
    • Georgia
      • Atlanta, Georgia, United States, 30322
        • Recruiting
        • Emory Children's Center
    • Indiana
      • Indianapolis, Indiana, United States, 46202
        • Recruiting
        • Indiana University Health University Hospital
    • Louisiana
      • Shreveport, Louisiana, United States, 71103
        • Recruiting
        • Louisiana State University
    • New Jersey
      • Hackensack, New Jersey, United States, 07601
        • Withdrawn
        • Hackensack University Medical Center
    • New York
      • Queens, New York, United States, 11042
        • Recruiting
        • Cohen Children's Medical Center of New York
    • Ohio
      • Cincinnati, Ohio, United States, 45229
        • Recruiting
        • Cincinnati Childrens Hospital
    • Pennsylvania
      • Philadelphia, Pennsylvania, United States, 19104
        • Withdrawn
        • Chldren?s Hospital of Philadelphia
    • Texas
      • El Paso, Texas, United States, 79902
        • Withdrawn
        • Texas Arthritis Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

12 years to 17 years (Child)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Participants who are age 12 to <18 years at the time of randomization
  • Participants who are age 5 to <12 years (younger participant cohort) at the time of randomization once recruitment is open. (Investigators will be notified by the Sponsor when recruitment is open to this younger population)
  • International Society of Nephrology and the Renal Pathology Society (ISN/RPS) 2003 Class III or IV active LN demonstrated on renal biopsy performed in the 12 months prior to or during screening
  • Class V disease may be present in addition to Class III or IV LN, but participants with isolated Class V disease are not eligible
  • Diagnosis of SLE according to the Systemic Lupus International Collaborating Clinics (SLICC) 2012 criteria
  • Significant proteinuria defined by a UPCR above > 0.5 based on a first-morning void (FMV) collection at screening
  • During the 12 months prior to or during screening, all participants must have received at least one dose of pulse-range IV methylprednisolone (typically 30 mg/kg, maximum of 1000 mg per dose) or equivalent for the treatment of the current episode of active LN.

Exclusion Criteria:

  • Severe, active central nervous system (CNS) SLE, including retinitis, poorly controlled seizure disorder, acute confusional state, myelitis, stroke, cerebellar ataxia, or dementia
  • Sclerosis in >50% of glomeruli on renal biopsy
  • Purely chronic Class III(c) or Class IV(c) disease on renal biopsy, defined as the absence of any active lesions
  • Presence of rapidly progressive glomerulonephritis
  • Pure Class V LN
  • Intolerance or contraindication to study therapies
  • Active infection of any kind (excluding fungal infection of nail beds) or any major episode of infection requiring hospitalization or treatment with IV anti-infective medications within 4 weeks prior to screening, or completion of oral anti-infectives within 2 weeks prior to randomization
  • History of or currently active primary or secondary immunodeficiency, including known history of HIV infection and other severe Immunodeficiency blood disorders
  • History of serious recurrent or chronic infection
  • History of or current cancer, including solid tumors, hematological malignancies, and carcinoma in situ (except basal cell carcinoma and squamous cell carcinoma of the skin that have been excised and cured) within the past 5 years
  • Significant or uncontrolled concomitant medical disease which, in the investigator's opinion, would preclude participant participation
  • Currently active alcohol or drug abuse or history of alcohol or drug abuse

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Placebo Comparator: Placebo
Placebo participants will receive obinutuzumab matched placebo on Day 1, Day 14, Week 24, Week 26 and Week 52.
Drug: Mycophenolate Mofetil
Mycophenolate Mofetil (MMF) will be taken by home administration orally at a target dose of 1200 mg/m^2/day to a maximum of 2.5g/day from baseline (Day 1) onwards.
Drug: Acetaminophen/paracetamol
Acetaminophen 1000 mg will be administered as pre-medication prior to infusions.
Drug: Diphenhydramine hydrochloride (HCl)
Diphenhydramine HCl 50 mg will be administered as pre-medication prior to infusions.
Drug: Methylprednisolone
Methylprednisolone 80 mg IV will be administered as pre-medication prior to infusions.
Drug: Prednisone
Oral prednisone or equivalent corticosteroid will be taken by home administration daily to a maximum dose of 60mg/day followed by a guided taper to 5mg/day or less by Week 24.
Drug: Placebo
Placebo matching obinutuzumab will be administered by IV on Day 1, Day 14, Week 24, Week 26 and Week 52.
Experimental: Blinded Obinutuzumab
Participants will receive obinutuzumab 1000 milligrams (mg) intravenous (IV) infusions on Day 1, Day 14, Week 24, Week 26 and Week 52. Participants with a body weight of 45 kg or more will receive the 1000 mg dose. Participants with a body weight below 45 kg will receive a weight adjusted dose of 20 mg/kilogram (kg).
Drug: Obinutuzumab
Obinutuzumab will be administered by IV infusion at a dose of 1000 mg on Day 1, Day 14, Week 24, Week 26 and Week 52.
Other Names:
  • Gazyva
Drug: Mycophenolate Mofetil
Mycophenolate Mofetil (MMF) will be taken by home administration orally at a target dose of 1200 mg/m^2/day to a maximum of 2.5g/day from baseline (Day 1) onwards.
Drug: Acetaminophen/paracetamol
Acetaminophen 1000 mg will be administered as pre-medication prior to infusions.
Drug: Diphenhydramine hydrochloride (HCl)
Diphenhydramine HCl 50 mg will be administered as pre-medication prior to infusions.
Drug: Methylprednisolone
Methylprednisolone 80 mg IV will be administered as pre-medication prior to infusions.
Drug: Prednisone
Oral prednisone or equivalent corticosteroid will be taken by home administration daily to a maximum dose of 60mg/day followed by a guided taper to 5mg/day or less by Week 24.
Experimental: Open-Label Obinutuzumab
Younger participants aged 5 to <12 will receive obinutuzumab 1000 mg IV infusions on Days 1, 14, Week 24, Week 26 and Week 52.
Drug: Obinutuzumab
Obinutuzumab will be administered by IV infusion at a dose of 1000 mg on Day 1, Day 14, Week 24, Week 26 and Week 52.
Other Names:
  • Gazyva
Drug: Mycophenolate Mofetil
Mycophenolate Mofetil (MMF) will be taken by home administration orally at a target dose of 1200 mg/m^2/day to a maximum of 2.5g/day from baseline (Day 1) onwards.
Drug: Acetaminophen/paracetamol
Acetaminophen 1000 mg will be administered as pre-medication prior to infusions.
Drug: Diphenhydramine hydrochloride (HCl)
Diphenhydramine HCl 50 mg will be administered as pre-medication prior to infusions.
Drug: Methylprednisolone
Methylprednisolone 80 mg IV will be administered as pre-medication prior to infusions.
Drug: Prednisone
Oral prednisone or equivalent corticosteroid will be taken by home administration daily to a maximum dose of 60mg/day followed by a guided taper to 5mg/day or less by Week 24.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Percentage of Participants who Achieve a Complete Renal Response (CRR) (AP)
Time Frame: Week 76

CRR is defined as achievement of all of the following:

  • Urinary protein-to-creatinine ratio (UPCR) <0.5 g/g
  • Estimated Glomerular Filtration Rate (eGFR) >=85% of baseline
  • No occurrence of intercurrent events
Week 76
Percentage of Participants with Adverse Events (PP)
Time Frame: Baseline to Week 76
Baseline to Week 76

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Percentage of Participants Achieving a CRR (AP)
Time Frame: Weeks 24 and 52
Weeks 24 and 52
Percentage of Participants who Achieve CRR with Successful Prednisone Taper (AP)
Time Frame: Week 76
Week 76
Percentage of Participants who Achieve a PRR (AP)
Time Frame: Week 76
Week 76
Percentage of Participants Achieving an Overall Response (CRR or PRR) (AP)
Time Frame: Weeks 24, 52, and 76

PRR is defined as:

achievement of all of the following:

  • >=50% reduction in urinary protein-to-creatinine ratio (UPCR) from baseline
  • UPCR < 1 g/g (or < 3 g/g if the baseline UPCR was >=3 g/g)
  • eGFR >=85% of baseline
  • No occurrence of intercurrent events
Weeks 24, 52, and 76
Change in UPCR (AP)
Time Frame: Baseline to Week 76
Baseline to Week 76
Change in eGFR (AP)
Time Frame: Baseline to Week 76
Baseline to Week 76
Time to Onset of CRR over the Course of 76 weeks (AP)
Time Frame: Up to Week 76
Up to Week 76
Percentage of Participants who Experience Treatment Failure (AP)
Time Frame: Week 12 to Week 76
Week 12 to Week 76
Change in anti-dsDNA titers (AP)
Time Frame: Baseline to Week 76
Baseline to Week 76
Change in C3 Complement Levels (AP)
Time Frame: Baseline to Week 76
Baseline to Week 76
Change in C4 Complement Levels (AP)
Time Frame: Baseline to Week 76
Baseline to Week 76
Percentage of Participants with Adverse Events According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0 (AP)
Time Frame: Baseline to Week 76
Baseline to Week 76
Serum Concentrations of Obinutuzumab (AP)
Time Frame: Baseline to Week 76
Baseline to Week 76
Percentage of Participants Achieving B-cell Depletion (AP)
Time Frame: Baseline, Weeks 4, 24, 52 and 76
Baseline, Weeks 4, 24, 52 and 76
Change in Pediatric Quality of Life Inventory-Multidimensional Fatigue Scale (PedsQL)-Fatigue Total Score (AP)
Time Frame: Baseline to Week 76
Baseline to Week 76
Change in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) (AP)
Time Frame: Baseline to Week 76
Baseline to Week 76
Change from Baseline in Child Health Questionnaire-Parent Form 28 (CHQ-PF28) Domain Scores (AP)
Time Frame: Baseline to Week 76
Baseline to Week 76
Percentage of Participants with Anti-drug Antibodies (ADA) (AP)
Time Frame: Weeks 0, 24, 52 and 76
Weeks 0, 24, 52 and 76
Relationship Between ADA Status and Percentage of Participants Achieving a CRR (AP)
Time Frame: Weeks 24, 52 and 76
Weeks 24, 52 and 76
Percentage of Participants Achieving a CRR (PP)
Time Frame: Week 76
Week 76
Percentage of Participants Achieving an Overall Response (PP)
Time Frame: Week 76

PRR is defined as achievement of all of the following:

  • >=50% reduction in UPCR from baseline
  • UPCR < 1 g/g (or < 3 g/g if the baseline UPCR was >=3 g/g)
  • eGFR >=85% of baseline
  • No occurrence of intercurrent events
Week 76
Percentage of Participants who Achieve CRR with Successful Prednisone Taper (PP)
Time Frame: Week 76
Week 76
Change in eGFR (PP)
Time Frame: Baseline to Week 76
Baseline to Week 76
Percentage of Participants Achieving B-cell Depletion (PP)
Time Frame: Baseline, Weeks 4, 24, 52 and 76
Baseline, Weeks 4, 24, 52 and 76
Percentage of Participants with ADAs (PP)
Time Frame: Weeks 0, 24, 52 and 76
Weeks 0, 24, 52 and 76
Change in anti-dsDNA titers (PP)
Time Frame: Baseline to Week 76
Baseline to Week 76

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Hoffmann-La Roche

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
Genentech, Inc.

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Director: Clinical Trials, Hoffmann-La Roche

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
May 12, 2022

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
June 15, 2028

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
June 14, 2030

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
September 1, 2021

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
September 1, 2021

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
September 9, 2021

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
June 3, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
June 1, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
June 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • WA42985
  • 2021-000097-29 (EudraCT Number)
  • 2023-505825-15-00 (Other Identifier: EU CT Number)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Lupus Nephritis

Clinical Trials on Obinutuzumab

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings